Start here if you're new
what it is
Myomo makes custom arm braces that help people with weak arms do daily tasks.
how it gets paid
Last year Myo made $41M in revenue. Direct-to-patient MyoPro sales was the main engine at $18M, or 44% of sales.
why it's growing
Revenue grew 25.7% last year. Revenue was $30M because it was 193% higher than last year.
what just happened
Revenue hit $30M, but EPS was still -$0.28.
At a glance
C++ balance sheet — some cracks in the foundation
25/100 earnings predictability — expect surprises
-$0.16 fy2024 eps est
$2B fy2026 rev est
35.2% operating margin
xvary composite: 31/100 — weak
What they do
Myomo makes custom arm braces that help people with weak arms do daily tasks.
custom fabricated → made for one body → your brace is not a shelf item. Myomo sold $41M last year with 184 employees, or about $223k per worker, which is a tiny team carrying real money. gross margin → profit after product costs → 64.6% means the device still has room before overhead eats it.
How they make money
$41M
annual revenue · their business grew +25.7% last year
Direct-to-patient MyoPro sales
$18M
+30.0%
Veterans Health Administration
$9M
+24.0%
Orthotics & Prosthetics providers
$7M
+21.0%
International distributors
$5M
+35.0%
Accessories, fittings, and replacements
$2M
+15.0%
The products that matter
wearable robotic arm brace
MyoPro
$40.9M · effectively 100% of revenue
it drove all $40.9M of 2025 revenue. That makes execution easy to track and concentration risk impossible to hide.
single product
Key numbers
$41M
ttm revenue
That is the whole company today. Growth is the only reason the stock exists.
25.7%
revenue growth
Sales rose faster than the company can earn a profit. The gap is still the story.
64.6%
gross margin
After product costs, Myomo keeps 64.6 cents of each dollar before overhead.
$10M
long-term debt
Debt is 28% of capital, so the balance sheet is not a cushion.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $10M (28% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for MYO right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $30M, but EPS was still -$0.28.
Sales jumped 193% vs. prior year. Gross margin was 64.6%, which says the device still makes money before overhead.
$30M
revenue
-$0.28
eps
64.6%
gross margin
the number that mattered
Revenue was $30M because it was 193% higher than last year.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk is MyoPro demand slowing before cash flexibility improves.
high
cash burn and limited balance-sheet room
The company carries a C++ balance sheet, $10M of long-term debt, and a risk rank of 5. That is a narrow margin for error, not a patient turnaround setup.
If revenue slips or costs outrun plan, financing risk becomes part of the story fast.
high
single-product concentration
MyoPro drives essentially 100% of revenue. Any reimbursement issue, product problem, regulatory setback, or competitive pressure hits the whole business at once.
One device line carries essentially all $40.9M of sales. That concentration is the business model risk.
med
patient funnel conversion risk
New patient candidates were 676 in Q4, up 3% from last year. The prior quarter grew 28%. That kind of deceleration is how future revenue misses start.
If candidate additions do not improve, the $43M–$46M guide range gets harder to defend.
med
governance pressure
Institutional ownership is cited at 45%, and Horton Capital Partners has filed a 13D tied to governance changes. That can sharpen accountability or consume management attention.
For a $27M company, one active holder is not background noise. It is part of the operating setup.
A slowdown in one device line exposes essentially all $40.9M of revenue, and the C++ balance sheet leaves little cushion if that slowdown persists.
source: institutional data · regulatory filings · risk analysis
Pay attention to
funnel health
new patient candidate growth
Q4 delivered 676 new candidates, up 3% from last year. That is the leading indicator the whole story now runs through.
next catalyst
Q1 2026 earnings
This is the first real check on whether the company is tracking toward its $43M–$46M revenue guide.
cost control
OpEx growth versus revenue growth
Management wants operating expense growth at roughly half of revenue growth. If that ratio breaks, balance-sheet pressure gets louder.
ownership tension
Horton Capital's governance push
A 5%+ holder filing a 13D is not background noise for a $27M company. Watch for board-level or strategic fallout.
Analyst rankings
earnings predictability
25 / 100
Low predictability means results can swing from quarter to quarter. In human-speak, analysts do not trust this business to print smooth numbers yet.
beta
1.3
Beta measures how much a stock tends to move versus the market. At 1.3, MYO has moved more than the index, which fits a volatile small-cap commercialization story.
source: institutional data
Institutional activity
institutional ownership data for MYO is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive